Definition
Description
Top Gene Interactions
Related Pathways
General Information
- Metabolism: The metabolism of is Oxazepam hepatic. Moreover, it is a metabolite of diazepam, prazepam and temazepam. Therefore, there is likely an overlap in possible interactions with other drugs or food, with exception of the pharmacokinetic CYP450 interactions (e.g. with cimetidine). [Wikipedia]. No active metabolites. It is hepatically metabolized and undergoes glucuronidation. The glucuronidation of the S-isomer is catalyzed by UGT2B15. The glucuronidation of the R-isomer is catalyzed by UGT2B7 and UGT1A9. Route of Elimination: This product has a single, major inactive metabolite in man, a glucuronide excreted in the urine. Half Life: Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)
- Uses/Sources: used extensively since the 1960s for the treatment of anxiety and insomnia and in the control of symptoms of alcohol withdrawal. [Wikipedia]
- Health Effects: They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
- Symptoms: Symptoms of overdose include confusion, drowsiness, and lethargy.
- Treatment: Induced vomiting and/or gastric lavage should be undertaken, followed by general supportive care, monitoring of vital signs, and close observation of the patient. Hypotension, though unlikely, usually may be controlled with norepinephrine bitartrate Injection. The value of dialysis has not been adequately determined for oxazepam. The benzodiazepine antagonist flumazenil may be used In hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. (L1712)
- Route of Exposure: Well absorbed from the gastrointestinal tract following oral administration however is absorbed at a slower rate compared to other benzodiazepines like diazepam or flurazepam. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration.
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
Estrogen receptor Androgen receptor Gamma-aminobutyric acid receptor subunit alpha-2 Gamma-aminobutyric acid receptor subunit alpha-3 Gamma-aminobutyric acid receptor subunit alpha-4 Gamma-aminobutyric acid receptor subunit alpha-5 Gamma-aminobutyric acid receptor subunit alpha-6 Gamma-aminobutyric acid receptor subunit beta-1 Gamma-aminobutyric acid receptor subunit beta-2 Gamma-aminobutyric acid receptor subunit beta-3 Gamma-aminobutyric acid receptor subunit delta Gamma-aminobutyric acid receptor subunit gamma-2 Gamma-aminobutyric acid receptor subunit gamma-3 Gamma-aminobutyric acid receptor subunit pi Gamma-aminobutyric acid receptor subunit rho-1 Gamma-aminobutyric acid receptor subunit rho-2 Gamma-aminobutyric acid receptor subunit gamma-1 Gamma-aminobutyric acid receptor subunit rho-3 Gamma-aminobutyric acid receptor subunit theta Gamma-aminobutyric acid receptor subunit epsilon Translocator protein GABA-A receptor (anion channel) |
17016423 2867566 6738302 17139284 18384456 11752090 23611293 |
|
Serum albumin Gamma-aminobutyric acid receptor subunit alpha-1 |
Oxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. |
17016423 4004929 17139284 4860 18348514 6863427 |
Oxazepam Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Prostatic Neoplasms | 11.76 |
|
Diabetes Mellitus, Experimental | 9.71 |
|
Mammary Neoplasms, Experimental | 8.73 |
|
Mesothelioma, Malignant | 8.67 |
|
Colonic neoplasm | 8.41 |
|
Adrenocortical Carcinoma | 8.05 |
|
Mammary Neoplasms, Animal | 7.33 |
|
Reperfusion Injury | 7.01 |
|
Diabetes Mellitus, Type 2 | 6.83 |
|
Lung Neoplasms | 6.81 |
|
Intestinal Neoplasms | 6.73 |
|
Uterine Cervical Neoplasms | 6.6 |
|
Carcinoma | 6.36 |
|
Urinary Bladder Neoplasms | 6.34 |
|
Cataract, Pulverulent, Juvenile-Onset | 6.27 |
|
Lung adenocarcinoma | 6.23 |
|
Mesothelioma | 6.18 |
|
Cholestasis, Intrahepatic | 6.06 |
|
Cholestasis | 6.03 |
|
Esophageal squamous cell carcinoma | 6.02 |
|